1. Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer

   • Arielle Heeke
   • Maria Raquel Nunes
   • Filipa Lynce

   Systemic Therapies (M Liu and T Haddad, Section Editors) Open access 25 October 2018 Pages: 241 - 250

2. Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy

   • Karthik V. Giridhar
   • Minetta C. Liu

   Systemic Therapies (M Liu and T Haddad, Section Editors) 19 November 2018 Pages: 251 - 261

3. Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer

   • Evanthia T. Roussos Torres
   • Roisin M. Connolly

   Systemic Therapies (M Liu and T Haddad, Section Editors) 06 November 2018 Pages: 262 - 273

   

4. Novel Agents for the Management of Endocrine Resistant Breast Cancer

   • Sonya Reid-Lawrence
   • Ingrid A. Mayer

   Systemic Therapies (M Liu and T Haddad, Section Editors) 15 November 2018 Pages: 274 - 281

5. Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)

   • Zorawar S. Noor
   • Aashini Master

   Clinical Trials (PF Peddi, Section Editor) 06 October 2018 Pages: 282 - 288

6. Updates on Molecular Classification of Triple Negative Breast Cancer

   • Nkiruka Ezenwajiaku
   • Cynthia X. Ma
   • Foluso O. Ademuyiwa

   Clinical Trials (PF Peddi, Section Editor) 24 September 2018 Pages: 289 - 295

7. Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018

   • Rashmi K. Murthy
   • Mariana Chavez-MacGregor
   • Gabriel N. Hortobagyi

   Clinical Trials (PF Peddi, Section Editor) 27 July 2018 Pages: 296 - 306

   

8. Phased Implementation as a Strategy for Stepwise, Sustainable Improvement in Breast Healthcare in Low-Resource Settings

   • Catherine Duggan
   • Benjamin O. Anderson

   Global Breast Cancer (BO Anderson and C Duggan, Section Editors) 20 October 2018 Pages: 307 - 312

9. Non-hormonal Chemoprevention

   • Naomi Hodde
   • Marie E. Wood

   Risk and Prevention (ME Wood, Section Editor) 23 October 2018 Pages: 313 - 318